Ichnos Glenmark Innovation Advances Cancer Therapy with ISB 2301 IND Submission to FDA

Ichnos Glenmark Innovation Takes a Major Step in Cancer Treatment



In a significant move toward innovative cancer treatments, Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology firm, has recently submitted an application for Investigational New Drug (IND) approval for its groundbreaking therapy, ISB 2301, to the U.S. Food and Drug Administration (FDA). This submission marks a pivotal moment in IGI's journey to revolutionize oncology with its Multispecific™ therapies.

ISB 2301 is designed as a first-in-class multispecific immune cell activator that specifically targets solid tumors. It operates by engaging both T lymphocytes and natural killer (NK) cells, presenting a novel approach to the treatment of cancer. The compound uniquely combines the targeting of three tumor-associated antigens (TAAs) while simultaneously activating both T and NK cells, addressing the challenging heterogeneity and immunosuppressive characteristics often exhibited by solid tumors.

Dr. Lida Pacaud, President and CEO of IGI, emphasized the importance of this development, stating, "The IND submission for ISB 2301 represents a critical milestone in advancing our multispecific oncology pipeline into clinical development. This pentaspecific candidate is meticulously crafted to integrate multiple tumor-targeting functionalities and immune mobilization within a single molecule. Our preclinical results have showcased a compelling anticancer profile for ISB 2301, which we firmly believe is distinctly different from existing therapies. We anticipate commencing a Phase 1 clinical trial for ISB 2301 in solid tumor patients in 2027."

The clinical potential of ISB 2301 is supported by IGI’s proprietary BEAT® platform, which demonstrates its ability to recognize multiple tumor-associated antigens while engaging T and NK cells through various complementary mechanisms. These mechanisms include antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition, and the induction of a robust type 1 immune response.

Preclinical studies of ISB 2301 have revealed favorable pharmacokinetic profiles and tolerability in non-human primates, setting promising foundations for its safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity analysis in patients with advanced solid tumors.

About Ichnos Glenmark Innovation, Inc.
IGI is a fully integrated, clinical-stage biotechnology company headquartered in New York, focusing on the development of innovative biologics in oncology. Building a robust portfolio of first-in-class Multispecific™ products, IGI leverages its proprietary technology platform, BEAT®, to create transformative therapies. The platform has shown clinical validity, particularly with ISB 2001, a trispesific T-cell activator that has exhibited promising antitumor activity and a favorable safety profile in heavily treated multiple myeloma patients in a Phase 1 experimental study.

IGI remains committed to developing breakthrough curative therapies that enhance and prolong the lives of patients battling malignant hematological diseases and solid tumors. For more information about IGI and its innovative approaches to cancer treatment, visit IGInnovate.com.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.